NVILE forecast ·
AbbVie (ABBV) Stock Forecast: Next 30 Days
Over the next 30 days, AbbVie (ABBV) has an 80% calibrated price range of $268.86 to $314.24 based on normal volatility distribution around its current $288.84 level. The probability of an increase greater than 10% is 8%, while the probability of a drop greater than 10% is 4%. Expected value sits at $290.67, representing a neutral midpoint rather than a directional forecast.
Price now
$288.84
Nov 2, 2026
In 30 days
$290.67
NVILE forecast
Expected move
+0.6%
Range
$268.86–$314.24
What to do
- Structure short-term positioning around the 80% distribution boundaries ($268.86 to $314.24).Historical price volatility supports range-bound risk rather than directional breakout over 30 days.
- Monitor quarterly revision trends and upcoming trial readout milestones for ABBV-RGX-314.[1],[4]Recent mixed revision breadth (5 down, 2 up) indicates potential near-term sentiment sensitivity.
Why
- ABBV is projected within an 80% distribution band between $268.86 and $314.24 over a 30-day horizon, centered around $290.67 without tested directional drift.
- Wall Street 12-month mean price target stands at $305.58 with current-quarter EPS revised upwards by +0.6% over 30 days, though 5 analysts recently cut vs 2 raised.[4]
- Short-sale volume share declined to 14.2% on November 2, 2026, below its 5-day average of 30.8% and 20-day average of 36.9%.[3]
- AbbVie and REGENXBIO are advancing pivotal Phase IIb/III trials for gene therapy ABBV-RGX-314 in wet AMD and diabetic retinopathy.[1]
- AbbVie expanded infrastructure via a July 2026 Arizona device facility acquisition and investments in two new Illinois manufacturing sites for neuroscience and obesity.[5]
What could go wrong
How it connects
- AbbVie Inc.executed collaboration agreement amendment withREGENXBIO Inc.[1]
- AbbVie Inc.co-develops retinal gene therapyABBV-RGX-314[1]
- REGENXBIO Inc.co-develops one-time treatment with AbbVieABBV-RGX-314[1]
- Nicholas Donoghoesold 32,710 shares of common stock for $8.18MAbbVie Inc.[2]
- AbbVie Inc.announced voluntary agreement to advance product affordability withU.S. Government[5]
- FINRAtracks and reports daily short-sale volume forAbbVie Inc.[3]
- Securities and Exchange Commissionreceives quarterly and insider filings fromAbbVie Inc.[2],[5]
NVILE's track record on this page
| Made | Forecast | Actual | Result |
|---|---|---|---|
| Nov 3, 2026 | $290.67 | Due Dec 3, 2026 | Pending |
Every published call is scored when it comes due. See all results →
Sources
Questions
What is the AbbVie forecast for the next 30 days?
NVILE's models put AbbVie at about $290.67 in 30 days, +0.6% from $288.84. Over the next 30 days, AbbVie (ABBV) has an 80% calibrated price range of $268.86 to $314.24 based on normal volatility distribution around its current $288.84 level. The probability of an increase greater than 10% is 8%, while the probability of a drop greater than 10% is 4%. Expected value sits at $290.67, representing a neutral midpoint rather than a directional forecast.
What price range does NVILE expect for AbbVie?
The forecast range is $268.86 to $314.24 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.
What could change the AbbVie outlook?
Recent analyst revisions tilt negative, with 5 cuts versus 2 raises on current-quarter EPS estimates over the last 30 days. Insider selling was recorded with Nicholas Donoghoe selling 32,710 shares for $8.18M in August 2026 at $250.00.
What should investors watch or do about AbbVie?
Structure short-term positioning around the 80% distribution boundaries ($268.86 to $314.24). Monitor quarterly revision trends and upcoming trial readout milestones for ABBV-RGX-314.
How accurate are NVILE forecasts?
Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.
This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.